Abstract: Amorphous solid dispersions of nilotinib fumarate or nilotinib tartrate are provided, as well as pharmaceutical compositions thereof, wherein the compositions exhibit enhanced bioavailability in the fasted state. Preferably, the compositions may be orally administered to a patient in either the fed or fasted state, with a decrease or elimination of the food effect. Preferably, following oral administration of the pharmaceutical compositions, there is no substantial difference in the pharmacokinetic parameters (e.g., Cmax, AUC0-t and/or AUC0-infinity) of nilotinib, regardless of whether the pharmaceutical compositions are administered to a subject in the fed or fasted state.

Abstract: Amorphous solid dispersions of nilotinib fumarate or nilotinib tartrate are provided, as well as pharmaceutical compositions thereof, wherein the compositions exhibit enhanced bioavailability in the fasted state. Preferably, the compositions may be orally administered to a patient in either the fed or fasted state, with a decrease or elimination of the food effect. Preferably, following oral administration of the pharmaceutical compositions, there is no substantial difference in the pharmacokinetic parameters (e.g., Cmax, AUC0-t and/or AUC0-infinity) of nilotinib, regardless of whether the pharmaceutical compositions are administered to a subject in the fed or fasted state.

Abstract: The present invention relates to a continuous micro-electro-flow reactor system for ultra-fast, oxidant free, C—C coupling reaction for making symmetrical biaryls and analogs thereof. This invention further relates to the said process for preparation of antiviral drug, daclatasvir of general formula I.

Abstract: Amorphous solid dispersions of nilotinib fumarate or nilotinib tartrate are provided, as well as pharmaceutical compositions thereof, wherein the compositions exhibit enhanced bioavailability in the fasted state. Preferably, the compositions may be orally administered to a patient in either the fed or fasted state, with a decrease or elimination of the food effect. Preferably, following oral administration of the pharmaceutical compositions, there is no substantial difference in the pharmacokinetic parameters (e.g., Cmax, AUC0-t and/or AUC0-infinity) of nilotinib, regardless of whether the pharmaceutical compositions are administered to a subject in the fed or fasted state.

Abstract: Solid dispersions of lurasidone or a pharmaceutically acceptable salt thereof are described, as well as pharmaceutical formulations thereof, and methods for making such formulations. Preferably, the solid dispersions are prepared by hot-melt extrusion or spray-drying, and comprise lurasidone with a pharmaceutically acceptable carrier (e.g., hydroxypropyl methyl cellulose acetate succinate (HPMC-AS), polyvinyl pyrrolidine vinyl acetate (PVP/VA) copolymer, hydroxypropyl methylcellulose phthalate (HPMCP), or mixtures thereof). The pharmaceutical composition may be orally administered to a patient in either the fed or fasted state, with a decrease or elimination of the food effect. Preferably, following oral administration of the pharmaceutical compositions, there is no substantial difference in the pharmacokinetic parameters (e.g., Tmax, Cmax, AUC0-t and/or AUC0-infinity) of lurasidone, regardless of whether the pharmaceutical compositions are administered to a subject in the fed or fasted state.

Abstract: Solid dispersions of lurasidone or a pharmaceutically acceptable salt thereof are described, as well as pharmaceutical formulations thereof, and methods for making such formulations. Preferably, the solid dispersions are prepared by hot-melt extrusion or spray-drying, and comprise lurasidone with a pharmaceutically acceptable carrier (e.g., hydroxypropyl methyl cellulose acetate succinate (HPMC-AS), polyvinyl pyrrolidine vinyl acetate (PVP/VA) copolymer, hydroxypropyl methylcellulose phthalate (HPMCP), or mixtures thereof). The pharmaceutical composition may be orally administered to a patient in either the fed or fasted state, with a decrease or elimination of the food effect. Preferably, following oral administration of the pharmaceutical compositions, there is no substantial difference in the pharmacokinetic parameters (e.g., Tmax, Cmax, AUC0-t and/or AUC0-infinity) of lurasidone, regardless of whether the pharmaceutical compositions are administered to a subject in the fed or fasted state.

Abstract: The present invention provides stable, ready-to-use injectable pharmaceutical compositions, comprising the combination of neostigmine, glycopyrrolate, a stabilizing amount of one or more aminopolycarboxylic acids, and a pharmaceutically acceptable liquid vehicle. Other aspects of the invention relate to methods for making such compositions and methods of using such compositions for reversing the effects of non-depolarizing neuromuscular blocking agents. Preferably, the composition comprises neostigmine methylsulfate, glycopyrronium bromide, ethylenediaminetetraacetic acid (EDTA) and a pharmaceutically acceptable liquid vehicle, and is provided in a pre-filled, ready-to-use sealed container, such as a pre-filled syringe, suitable for intravenous administration.

Abstract: The present invention provides stable, ready-to-use injectable pharmaceutical compositions, comprising the combination of neostigmine, glycopyrrolate, a stabilizing amount of one or more aminopolycarboxylic acids, and a pharmaceutically acceptable liquid vehicle. Other aspects of the invention relate to methods for making such compositions and methods of using such compositions for reversing the effects of non-depolarizing neuromuscular blocking agents. Preferably, the composition comprises neostigmine methylsulfate, glycopyrronium bromide, ethylenediaminetetraacetic acid (EDTA) and a pharmaceutically acceptable liquid vehicle, and is provided in a pre-filled, ready-to-use sealed container, such as a pre-filled syringe, suitable for intravenous administration.

Abstract: The present invention provides stable pharmaceutical compositions, comprising a pharmaceutically effective amount of testosterone or a pharmaceutically acceptable ester thereof, a pharmaceutically acceptable oil vehicle, and a stabilizing amount of benzyl alcohol, for example, about 1% to 3% weight/volume of benzyl alcohol. The present invention also provides a process for stabilizing testosterone-containing pharmaceutical compositions by ageing them at a temperature of about 20° C. to about 60° C. for at least 48 hours, e.g., prior to secondary packing and labeling. These compositions were stable over the shelf life of the product, without exhibiting crystal formation, even upon storing at temperatures of about 2° C. to about 8° C. Other aspects of the invention relate to methods for making such pharmaceutical compositions, and methods of using such pharmaceutical compositions for hormone replacement therapy, e.g.

Abstract: The present invention provides stable, ready-to-use pharmaceutical compositions, comprising dexmedetomidine or a pharmaceutically acceptable salt thereof, one or more pharmaceutically acceptable excipients, and a pharmaceutically acceptable liquid vehicle, where the composition is provided in a sealed container that comprises a cyclic olefin polymer. The present invention also provides ready-to-use pharmaceutical compositions comprising dexmedetomidine or a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable liquid vehicle and an antioxidant and/or stabilizer, such as L-methionine. These solutions were found to be stable over the shelf life of the product. Other aspects of the invention relate to methods for making such compositions, as well as methods of using such compositions for perioperative care of a patient or for sedation.

Abstract: The present invention deals with a mycoherbicidal isolate of Setosphaeria monoceras sp. or extracts obtained therefrom, useful for the control of Water hyacinth. The present invention also discloses biological control compositions comprising fungal isolate extract formulated in a growth medium for maintaining the viability of extract when the biological control composition is applied to weed. The present invention also discloses methods of screening fungal isolate to determine if they exhibit biocontrol activity. The present invention also discloses use of Setosphaeria monoceras strain. In yet a further aspect the invention relates to use of an Setosphaeria strain for producing a herbicidal agent effective for controlling growth of water hyacinth plants. The strain used preferably is a strain having the characterizing features of Setosphaeria strain AGWH#1 1 as deposited at IMTECH under accession number MTCC 5974.

Abstract: The present invention relates to a mainly herbal composition comprising Terminalia bellerica fruits (1-5% w/w) more particularly the extract of dried fruits. The composition further has exogenously added malonic acid, glutamic acid, eicosenoic acid and linolenic acid. The composition of present invention is useful in treatment and control of gastro intestinal problems like diarrhea, dysentery, ulcers etc. and used as an oral dosage form.

Abstract: The present invention deals with a mycoherbicidal isolate of Setosphaeria monoceras sp. or extracts obtained therefrom, useful for the control of Water hyacinth. The present invention also discloses biological control compositions comprising fungal isolate extract formulated in a growth medium for maintaining the viability of extract when the biological control composition is applied to weed. The present invention also discloses methods of screening fungal isolate to determine if they exhibit biocontrol activity. The present invention also discloses use of Setosphaeria monoceras strain. In yet a further aspect the invention relates to use of an Setosphaeria strain for producing a herbicidal agent effective for controlling growth of water hyacinth plants. The strain used preferably is a strain having the characterizing features of Setosphaeria strain AGWH#11 as deposited at IMTECH under accession number MTCC 5974.

Abstract: The present invention relates to a mainly herbal composition comprising Terminalia bellerica fruits (1-5% w/w) more particularly the extract of dried fruits. The composition further has exogenously added malonic acid, glutamic acid, eicosenoic acid and linolenic acid. The composition of present invention is useful in treatment and control of gastro intestinal problems like diarrhea, dysentery, ulcers etc. and used as an oral dosage form.

Abstract: Provisioning, managing and tracking of services provided by a cloud infrastructure system are described. A subscription request from a customer for one or more services provided by the cloud infrastructure system is received. Resources for the requested services are then provisioned. Resource usage information for the resources is collected and an overuse of the resources provisioned to the services in the subscription request, by a customer is determined. The overage information is provided to the customer.

Abstract: A method for conserving the power usage of access points in a WLAN is disclosed. The method includes detecting, by a peripheral access point during periods of low network usage, that a mobile device has entered a wireless network coverage area. The method also includes providing, by the peripheral access point, initial services to the mobile device and monitoring movements of the mobile device in the network coverage area. Upon determining that the mobile device is in a vicinity of a powered-off non-peripheral access point, powering on a first non-peripheral access point which is determined to be closest to the mobile device and a set of first concentric access points to provide a coverage buffer around the first access point and using the first non-peripheral access point and the set of first concentric access points as serving access points for the mobile device.

Abstract: Provisioning, managing and tracking of services provided by a cloud infrastructure system are described. A subscription request from a customer for one or more services provided by the cloud infrastructure system is received. Resources for the requested services are then provisioned. Resource usage information for the resources is collected and an overuse of the resources provisioned to the services in the subscription request, by a customer is determined. The overage information is provided to the customer.

Abstract: Ontology system providing enhanced search capability receives a search request specifying nodes and edges of interest and determines a set of matching ontologies stored in a knowledge store. The ontology system also generates a ranking for each of the matching ontologies based on the extent of matching. Data indicating the matching ontologies and corresponding rank is sent as a search result.

Abstract: Determination of a fast route from a source node to many destination nodes. Identities of each node, and bandwidths and latencies of paths are received. A threshold bandwidth is set, and routes containing paths among nodes which have an associated bandwidth exceeding the threshold bandwidth (or within a desired range, in general) are determined. The route providing the least latency among the routes thus determined is selected. The process is repeated for other values of threshold bandwidths, and the fastest route is then determined from the routes selected for each value of threshold bandwidth considered.

Abstract: Retrieving information from information sources using links. A set of information sources is preprocessed to extract content from text and existing links in the information sources according to some predetermined criteria. A set of search results is generated from amongst the preprocessed information sources in response to a received search query.